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Abstract 
Background: Currently, invasive physiologic assessment such as fractional flow reserve is widely used 
worldwide with different adoption rates around the globe. Patient characteristics and physician prefer-
ences often differ in the Asia-Pacific (APAC) region with respect to treatment strategy, techniques, lesion 
complexity, access to coronary physiology and imaging devices, as well as patient management. Thus, 
there is a need to construct a consensus document on recommendations for use of physiology-guided 
percutaneous coronary intervention (PCI) in APAC populations. This document serves as an overview 
of recommendations describing the best practices for APAC populations to achieve more consistent and 
optimal clinical outcomes.
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Methods and Results: A comprehensive multiple-choice questionnaire was provided to 20 interven-
tional cardiologists from 10 countries in the APAC region. Clinical evidence, tips and techniques, and 
clinical situations for the use of physiology-guided PCI in APAC were reviewed and used to propose key 
recommendations. There are suggestions to continue to develop evidence for lesion and patient types that 
will benefit from physiology, develop directions for future research in health economics and local data, 
develop appropriate use criteria in different countries, and emphasize the importance of education of 
all stakeholders. A consensus recommendation to enhance the penetration of invasive physiology-based 
therapy was to adopt the 5E approach: Evidence, Education, Expand hardware, Economics and Expert 
consensus. 
Conclusions: This consensus document and recommendations support interventional fellows and 
cardiologists, hospital administrators, patients, and medical device companies to build confidence and 
encourage wider implementation of invasive coronary physiology-guided therapy in the APAC region. 
(Cardiol J 2019; 26, 3: 215–225)
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Introduction
Coronary angiography can no longer be consid-
ered a gold standard for determining the functional 
significance of coronary stenosis given its known 
limitations including eccentric plaque morphol-
ogy, frequent lack of a normal reference segment, 
visual overestimation, and inter-observer variabil-
ity [1–3]. As a consequence of these limitations, 
intracoronary physiology assessment and imaging 
have been developed to provide superior diagnostic 
information for coronary stenotic lesions [4, 5]. 
Fractional flow reserve (FFR) was developed to 
define the functional significance of a coronary 
stenosis in a cardiac catheterization laboratory. 
In addition, resting pressure-derived physiologic 
indices have also been developed and used in daily 
clinical practice [6]. However, their penetration 
rate in the Asia-Pacific (APAC) region is highly 
variable and low in general.  
This consensus statement for the APAC region 
briefly reviews important clinical studies to de-
velop a practical message regarding when and how 
to use coronary physiology, and aims to promote 
physician education at different stages of adopting 
physiologic assessment into clinical practice. 
Methods
This paper is based on a meeting sponsored 
by Abbott Vascular in April 2018 of 20 interven-
tional cardiologists from 10 countries (Australia, 
China, India, Japan, Korea, Singapore, Taiwan and 
Thailand) with significant experience in perform-
ing physiology-guided percutaneous coronary 
intervention (PCI). The goal of the meeting was 
to understand invasive physiology practice across 
the APAC region and to develop a consensus state-
ment. A pre-meeting survey was followed by an 
interactive discussion. The participants included 
high-volume interventional cardiologists with ex-
tensive experience:
 — at least 300 PCIs performed per year;
 — ~2/3rd performing 6–10 physiology procedur-
es per month; 1/3rd performing more than 
10 physiology procedures per month;
 — 2/3rd administering intravenous hyperemia 
during physiology-guided PCI;
 — 2/3rd considering physiology during ST-seg-
ment elevation myocardial infarction (STEMI).
Clinical evidence, tips and techniques, and 
clinical situations for the use of physiology-guided 
PCI in APAC were reviewed and used to propose 
key recommendations. Against the backdrop of 
the available clinical evidence and the physicians’ 
personal experience, the group discussed multiple 
issues pertaining to physiology-guided PCI.
 — Lesion/patient subsets recommended and 
not recommended for invasive physiologic 
assessment;
 — Current evidence gaps and areas for further 
research;
 — Trends of differential utilization of coronary 
physiologic assessment;
 — Learning curve and barriers to routine adop-
tion of physiologic assessment; 
 — Impact of appropriate use criteria on phy- 
siologic assessment adoption in APAC count-
ries;
 — Resting physiology:
• clinical evidence about resting flow, 
• benefits and limitations of adopting rest-
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ing physiologic assessment into daily 
practice,
• role of non-hyperaemic resting ratios such 
as resting full-cycle ratio (RFR) or diastolic 
pressure ratio (dPR) to drive the adoption 
of invasive physiologic assessment;
 — Technologies to assess microvascular disease:
• current role of coronary flow reserve 
(CFR) and index of microcirculatory re-
sistance (IMR) in clinical practice, based 
on evidence,
• evidence gaps for CFR and IMR,
• relevance of CFR and IMR as a main-
stream clinical tool,
• role of CFR in clinical practice: current 
and future. 
Results and discussion
Key findings of the pre-meeting survey are 
as follows:
 — FFR was the most common physiology index, 
followed by IMR and instantaneous wave-free 
ratio (iFR);
 — Common criteria for considering physiology 
assessment in clinical practice were interme-
diate or ambiguous lesions and stenosis of bi-
furcation lesions, in-stent restenosis, left main 
lesions, multi-vessel disease, and STEMI. 
However, all agreed that stenosis severity 
alone should not be the sole gatekeeper for 
invasive physiologic assessment;
 — Adenosine was the hyperaemic agent of choice 
based on its availability. However, intracoro-
nary nicorandil was also considered as an alter-
native agent based on equivalent hyperaemic 
efficacy and significantly lower procedural time 
and patient discomfort [7, 8];
 — Cost and additional time needed to conduct the 
procedure were identified as the main factors 
preventing the routine use of physiologic as-
sessment. Multiple factors were identified as 
potentially being able to increase physiology-
-guided PCI. These are separately discussed 
as recommendations of the group;
 — Use of post-PCI physiology still remains an 
emerging area, with a majority of interven-
tional cardiologists using it in < 25% of the 
total number of physiology procedures;
 — Despite the latest evidence including theo-
retical support of reliability in FFR value and 
prognostic benefit of an FFR-guided strategy 
for non-culprit lesions during STEMI presen-
tation, more than 50% of respondents do not 
use it routinely;
 — The use of CFR and IMR as a physiological 
tool remains modest with only limited opera-
tors understanding its potential. Availability 
of more clinical evidence, better software, 
and a simplified clinical protocol may support 
adoption of CFR and IMR;
 — iFR, one of several pressure-derived physi-
ologic indices that avoids hyperaemia, has few 
users in the APAC regions as a routine proce-
dure. Some factors supporting iFR in practice 
include fewer side effects compared with FFR, 
faster procedural time and lower cost;
 — Education of all stakeholders (consultants, 
technicians, nursing staff, patients, referring 
physicians, and insurers) was identified as 
a key step and is discussed separately in the 
recommendations section.
Numerous factors influence treatment deci-
sion patterns and differ among countries. Physi-
cians will always rely on a combination of their 
knowledge, experience, and the guidelines to 
shape a therapeutic strategy. The following are 
a summary of issues discussed during the meeting. 
Current guidelines and clinical evidence
The latest update of the American College 
of Cardiology/American Heart Association (ACC/ 
/AHA) Guideline for the Diagnosis and Manage-
ment of Patients with Stable Ischemic Heart 
Disease states: “It has been suggested in several 
studies that a PCI (percutaneous coronary inter-
vention) strategy guided by FFR may be superior 
to a strategy guided by angiography alone.” [9]. In 
the absence of non-invasive proof of ischemia, FFR 
performed in a coronary stenosis with a 40–90% 
diameter reduction was given a “class I recommen-
dation” and “level of evidence A” in the guidelines 
for coronary revascularization published by the 
European Society of Cardiology (ESC) in 2019 
(Table 1) [10].
Based on the results of several randomized, 
prospective clinical studies and registries evalu-
ating physiology-guided PCI in many thousands 
of patients, the clinical relevance of FFR is well 
established and documented (Fig. 1). Even when 
non-invasive proof of ischemia is available, FFR 
measurements often change clinical judgment 
regarding the need to revascularize a given coro-
nary artery stenosis [11]. Table 2 shows the sum-
mary of studies which investigated the changes in 
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Table 1. Recommendations on functional testing and for lesion assessment — 2018 European Society 
of Cardiology/European Association for Cardio-Thoracic Surgery (ESC/EACTS) guidelines on myocardial 
revascularization.
Recommendations Class of recommendation Level of evidence
When evidence of ischaemia is not available, FFR or iFR  
are recommended to assess the hemodynamic relevance  
of intermediate-grade stenosis
I A
FFR-guided PCI should be considered in patients with  
multivessel disease undergoing PCI
IIa B
FFR — fractional flow reserve; iFR — instantaneous wave free ratio; PCI — percutaneous coronary intervention
Figure 1. A case of physiology guided percutaneous coronary intervention (PCI). A. A patient showed angiographi-
cally, two vessel disease with stenosis in left anterior descending artery (LAD) and left circumflex artery (LCX). How-
ever, fractional flow reserve (FFR) in LAD, LCX and right coronary artery (RCA) was 0.84, 0.79, and 0.66, respectively. 
In contrast to angiographic assessment, physiologic assessment showed that the targets of revascularization were 
LCX and RCA, not LAD. In RCA, significant pressure step-up occurred at the ostium (arrow); B. PCI was performed for 
proximal LCX and RCA lesions and post PCI FFR at LCX and RCA was 0.90 and 0.98, respectively. 
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management strategy after invasive physiologic 
assessment [12–17].
Key findings from previous pivotal FFR trials 
can be summarised as follows:
 — DEFER trial [18] showed that FFR-based 
deferral of revascularization for a functionally 
insignificant stenosis was safe in up to 15 years 
of follow-up, and revascularization of these le-
sions could not have improved the prognosis. 
The DEFER-DES trial [19], which was con-
ducted in the era of drug-eluting stents, also 
showed similar results to the DEFER trial;
 — FAME trial [20] showed that an FFR-guided 
strategy reduced the risk of major adverse 
cardiac events compared with an angiography-
guided strategy, with less use of stents per 
patient, contrast media, and medical cost. Re-
cently published 5-year follow-up data showed 
no late catch-up of events in the FFR-guided 
group;
 — FAME II trial [21] clearly showed that in 
patients with stable coronary artery disease 
(CAD), an initial FFR-guided PCI strategy re-
sulted in a sustained clinical benefit compared 
with medical therapy alone using a composite 
primary endpoint of death, myocardial infarc-
tion, or urgent revascularization at 5 years. 
Patients without hemodynamically significant 
stenosis had a favourable long-term outcome 
with medical therapy alone;
 — COMPARE ACUTE [22]: In patients with 
STEMI and multi-vessel disease who under-
went primary PCI of an infarct-related artery, 
the addition of immediate FFR-guided com-
plete revascularization of non-infarct-related 
arteries in the acute setting resulted in the risk 
of a composite cardiovascular outcome that 
was lower than the risk among those who were 
treated for the infarct-related artery only. This 
reduction was mainly driven by the decreased 
need for subsequent revascularization;
 — DANAMI-3-PRIMULTI [23]: In patients with 
STEMI and multi-vessel disease who under-
went primary PCI of an infarct-related artery, 
the addition of staged FFR-guided complete 
revascularization of non-infarct-related arter-
ies (median interval 2 days) resulted in the risk 
of a composite cardiovascular outcome that 
was lower than the risk among those who were 
treated for an infarct-related artery only. This 
reduction was mainly driven by a decreased 
need for subsequent revascularization [9].
Clinical application of resting  
physiologic indices
Recently, iFR was introduced as an alternative 
to FFR that does not require hyperaemia (Fig. 2). 
Two large randomized trials, the DEFINE-FLAIR 
[24] and the iFR-SWEDEHEART trial [25], claimed 
non-inferiority of iFR compared with FFR but did 
not focus on the 20% of lesions with discordant 
treatment decisions between iFR and FFR. In stud-
ies by Lee et al. [26–28], both iFR and FFR changed 
significantly according to different anatomical and 
hemodynamic stenosis severity. However, FFR 
showed more sensitive changes to the severity of 
a stenosis than iFR. Currently, European guidelines 
Table 2. Changes in management strategy after invasive physiologic assessment.
Trial [year] Subjects Pressure wire assessment Change in management strategy
DEFINE REAL  
(2018) [12]
Multivessel  
disease
FFR and/or iFR 
Intermediate lesions
26.9% (130 of 484 patients)
POST-IT  
(2016) [13]
FFR in ≥ 1 vessel FFR 
Operator’s discretion
44.2% (406 of 918 patients)
FAMOUS-NSTEMI 
(2015) [14]
NSTEMI FFR 
All lesions with  
≥ 30% stenosis
21.6% (38 of 176 patients)
CVIT-DEFER  
(2015) [15]
FFR in ≥ 1 vessel FFR 
Intermediate lesions
39.0% (1205 of 3093 patients)
R3F  
(2014) [16]
Ambiguous  
stenosis +
FFR 
Angiographically  
35% to 65% stenosis
43.2% (464 of 1,075 patients)
RIPCORD  
(2014) [17]
Stable chest pain FFR 
All coronary arteries  
≥ 2.25 mm
26.5% (53 of 200 patients)
FFR — fractional flow reserve; iFR — instantaneous wave free ratio; NSTEMI — non-ST-segment elevation myocardial infarction; PW — pres-
sure wire
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consider iFR as largely equivalent to FFR [9]. Inte-
gration of both resting and hyperaemic physiologic 
indices may provide better information for clinical 
decision-making as recent studies suggested that 
the discordance between iFR and FFR might have 
clinical implications [29–31]. In addition to iFR, 
resting physiologic indices such as dPR or diastolic 
hyperemia-free ratio and RFR have been introduced 
and showed equivalent diagnostic performance to 
iFR [32, 33]. As FFR is the most commonly used 
invasive physiologic index in the APAC region, 
further discussion is needed to provide a guide for 
use of resting indices in daily practice.
Role of microvascular assessment
Since the coronary artery system has three 
components (epicardial coronary arteries, arte-
rioles, and capillaries), myocardial ischemia can 
occur within any one of these levels. Although 
the microvascular system cannot be visualized by 
invasive coronary angiography, its function can be 
evaluated by invasive physiologic assessment. It 
is well-known that the presence of microvascular 
dysfunction is associated with a poor prognosis in 
patients who do not have significant epicardial CAD 
(Fig. 3). IMR is a specific index for microvascular 
status and can be measured by a thermodilution 
technique. CFR represents the microvascular 
status when there is no significant epicardial dis-
ease and can be measured using a Doppler wire 
or a pressure/temperature-sensor guide wire. 
The international IMR registry with 1,096 Asian 
and Western patients (1,452 vessels) found that 
there was no correlation between IMR and FFR 
values (r = 0.01; p = 0.62) and between IMR and 
angiographic percent diameter stenosis (r = −0.03; 
p = 0.25) [34]. The optimal cut off value in patients 
with stable CAD was 25 (arbitrary units). In a Korean 
study which investigated the prognosis of patients 
according to CFR and IMR levels, the presence of 
low CFR in conjunction with high IMR was the 
most powerful independent predictor for clinical 
events among patients with high FFR [35]. These 
results suggest that the use of invasive physiologic 
assessment for microvascular disease should be 
encouraged, as it can help identify patients at 
high risk for future cardiovascular events among 
those with high FFR. In order for microvascular 
assessment to be used more, the logistic and 
reimbursement issues need to be resolved, along 
with more education about microvascular disease 
and techniques for its assessment.
Global physiology practice
Invasive coronary physiology is used world-
wide now, with the first instance of resting coronary 
Figure 2. Resting and hyperemic pressure-derived invasive physiologic indices; abbreviations — see text.
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pressure across a stenosis recorded by Gruentzig 
et al. [36] during his initial PCI. Despite this early 
introduction, the practical use of coronary physiol-
ogy in the cardiac catheterization laboratory started 
only in the late 1990’s. FFR was first described by 
Pijls et al. [37] in 1993 and has been evaluated since 
then in numerous large randomized trials and real-
world registries. Tracking the uptake of coronary 
physiology by dividing the number of pressure 
wires by the number of PCI’s (albeit an imperfect 
metric) demonstrates an enormous growth in many 
parts of the world, including some APAC countries 
[38], as detailed in Table 3 [39–44].
Barriers for adoption of invasive  
physiologic assessment in a cardiac  
catheterization laboratory
Despite clear evidence and guideline recom-
mendations, many interventional cardiologists 
continue to rely on visual assessment of stenosis 
severity alone rather than using physiologic assess-
ment in a cardiac catheterization laboratory. Multiple 
reasons have been attributed to the differential use 
of physiology-guided PCI. These factors include:
 — logistics;
 — cost;
 — availability of hyperaemic agents;
 — extra-time for physiologic assessment;
 — concerns regarding potential complications;
 — uncertainty about optimal performance of 
physiology assessment;
 — relying on invasive imaging assessment;
 — interpretation of FFR measurements, par-
ticularly in complex situations, such as mul-
ti-vessel disease, left main disease, serial 
lesions, and patients with coronary artery 
bypass grafts. 
Although intracoronary pressure assessment 
is not technologically challenging to perform, sev-
Table 3. Public Reporting of Coronary Physiology Uptake [38]
Country Year PW PCI PW/PCI Temporal change Hospital-level reporting?
Sweden [39] 2017 NR NR 26% 3.1-fold in 10 years Yes
United Kingdom [40] 2016 18,811 100,483 19% 3.5-fold in 8 years Yes
Italy [41] 2016 11,000 218,751 5% 1.4-fold in 4 years Yes
Europe EAPCI [42] 2015 NR 889,957 16% 2-fold in 5 years Per country
United States [43] 2014 3,465* NR 31% 3.8-fold in 5 years No
Australia [44] 2015 NR 3,869 19% 100-fold in 9 years Per state
*Limited to a subset of the 59,375 patients in the National Cardiovascular Data Registry CathPCI Registry with lesions deemed 40–70% by 
visual assessment. EAPCI — European Association of Percutaneous Cardiovascular Interventions; NR — not reported; PCI — percutaneous 
coronary intervention; PW — intracoronary pressure wire
Figure 3. A case of microvascular disease assessed by coronary flow reserve (CFR) and index of microcirculatory 
resistance (IMR). The patient presented with typical chest pain on exertion and a positive exercise stress test. Coro-
nary angiography showed no obstructive epicardial coronary artery disease and fractional flow reserve (FFR) was 
insignificant in the left anterior descending artery (LAD). However, CFR was low and IMR was high in LAD, suggesting 
the presence of microvascular disease; hTmn — hyperemic mean transit time; Pd — mean distal coronary pressure.
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eral aspects were suggested to guarantee precise 
measurements: nitrate administration, proper wire 
position to avoid artefact, flushing and guide control 
to avoid damping or ventricularisation, and a post-
procedure drift check.
An important issue raised during the meeting 
was the cost and availability of different hyperae-
mic agents. Although the intravenous infusion of 
adenosine/ATP (140 µg/kg/min) is generally re-
garded as a gold standard hyperemic method, the 
use and availability of various hyperaemic agents 
differs among APAC regions. In Korea and Japan, 
the use of intracoronary nicorandil (2 mg bolus) 
and papaverine have become popular in clinical 
practice due to its safety, ease of use, and relatively 
long-acting effects [7, 8].
Recommendations that can increase  
coronary physiology uptake in  
APAC countries (5E Approach)
Evidence
Since most of the large randomized study data 
has been generated in Western countries, there is 
a clear need to generate local APAC real-world 
data. This could be either in the form of decision-
making strategy trials like RIPCORD, or in-country 
large registries like SCAAR (Sweden). Several 
groups of APAC countries recently published the 
results of important physiologic studies and those 
study results from APAC need to be highlighted 
[19, 26, 45–50]. The group also felt that in-country 
registry data can provide good scientific evidence 
to respective health authorities to incorporate inva-
sive physiology in guidelines and reimbursement. 
Cost effectiveness and clinical outcomes should be 
an integral part of such a platform. There may also 
be the potential of conducting ‘recovery audits’ of 
catheterization laboratories, just like those done 
in the United States.
Education
Education will play a significant role in es-
tablishing physiology-guided PCI as a standard 
practice. There was unanimous agreement to focus 
on younger interventional cardiologists and fellows 
and ensure that they are aware of the benefits of 
physiologic assessment. While this may be a chal-
lenge given the lack of learning opportunities in 
an individual hospital or center, academic societies 
and industry can play an important role in impart-
ing education at an early stage in their careers. 
This can be achieved through scientific agenda 
at important conferences, demonstration through 
live cases, expert tours etc. Involvement of cardiac 
catheterization laboratory technicians and nurses 
will also be crucial to the success of any physiology 
education program. They are important stakehold-
ers in the entire process and need to be included in 
the education strategy. The group also felt that it is 
extremely important to establish patient awareness 
of physiology-guided PCI. In different healthcare 
systems in APAC, given the varying reimburse-
ment structures, patient awareness efforts will 
play a key role in driving benefits of physiologic 
assessment. The group recommended a dedicated 
patient-centric approach that can address the po-
tential harm of ‘over-stenting’.
Expand capital penetration
Though a limited role exists for interventional 
cardiologists in improving product availability, the 
group recommended developing the infrastructure 
at small/medium centers, rather than just focusing 
on high volume centers. Sometimes large volume 
PCI centres may not fully understand the implica-
tions of such a technology and would be resistant 
to bring about any change in the existing set-up. 
Smaller volume hospitals tend to invest more in 
newer technology to continuously upgrade their 
infrastructure and quality of outcomes.
Economics
The group strongly felt that health economics 
would be one of the most important factors to im-
pact the adoption of physiology-guided PCI. There 
is a strong need to establish the cost effectiveness 
of the therapy through local registries as the bulk 
of the evidence has been generated in Western 
healthcare systems which are structured very 
differently than APAC healthcare. Positive health 
economy data will support reimbursement and, in 
turn, the utility of the therapy. 
Expert consensus
There is growing clinical evidence for the 
value of coronary physiologic assessment and 
its beneficial effect on outcomes of coronary in-
terventional procedures for patients. However, 
a common misconception among interventional 
cardiologists is that physiology may have a negative 
impact on the advancements of PCI procedures. 
Some interventional cardiologists believe that with 
increasing physiology-guided PCI, the number of 
overall PCI procedures will come down and this 
will discourage the value of the PCI procedures, 
and, as such, prefer stenting over physiologic as-
sessment. There is also a perception that the ad-
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dition of physiological measurements would lead 
to more time spent in the cardiac catheterization 
laboratory. In the absence of in-country guidelines 
or appropriate use criteria in most APAC countries, 
interventional cardiologists have been inconsistent 
in their approach to physiologic assessment. Lack 
of equipment for physiologic assessment and re-
imbursement in most APAC countries limits such 
procedures. Though health authorities in some 
countries have already started to develop guide-
lines around invasive physiologic assessment and 
considering reimbursement, there is still a long 
way to go before it becomes a part of the routine 
treatment protocol. 
Conclusions 
This consensus document and recommenda-
tions supports interventional fellows and cardiolo-
gists, hospital administrators, patients, and medical 
device companies to build confidence and encour-
age wider implementation of the invasive coronary 
physiology-guided therapy in the APAC region. 
More consensus meetings and targeted education 
are needed to guide the proper use of invasive 
physiologic assessment in the APAC region.
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